Posts

Cyclic peptides advance toward new drug targets, but manufacturing capacity may determine how fast

on

Lilly’s Foundayo Oral GLP-1 Prescriptions Cross 40,000

on

Enhertu gains a potential first-line foothold in HER2-mutant NSCLC, but oral TKIs remain credible competitors

on

Novo Nordisk Tests Lower Maintenance Doses of Oral Wegovy

on

Eli Lilly’s Foundayo builds scripts after a disappointing Q2 amid oral GLP‑1 race with Novo Nordisk’s Wegovy pill

on

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on

BridgeBio achondroplasia pill shows compelling growth and body proportionality benefit

on

4 years after FDA snub, GSK partnership propels Spero’s Utebzi across approval finish line

on

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

KOL Insight: HR‑Positive/HER2‑Negative Breast Cancer (June 1, 2026)

on

Design Therapeutics’ Friedreich’s Ataxia Data and Vincentage’s Obesity Results from China

on

Ambrosia Biosciences Raises $100M Series B for Oral GLP-1 Drug Development

on

Merck Touts Strong Comparator Data for Enlicitide Decanoate, Oral PCSK9 Inhibitor Reducing LDL-C by Up to 60% in Phase 3 Trials

on

How GLP-1 Weight Loss Compounders Reshaped the Drug Industry

on

Novo Nordisk's Wegovy Pill Launches Strongly Amid Analyst Caution

on

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

on